Erasca, Inc.
Erasca, Inc. is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Pharmaceutical Preparations.
The next scheduled catalyst is Next quarterly earnings (projected) on October 19, 2026, a projected date rather than a confirmed one. There are 4 upcoming events on record.
Cash runway is approximately 29.4 months based on the most recent reported cash position and quarterly operating burn as of 2026-06-30.
Across 5 concluded trials, 80% reached completion rather than being terminated or withdrawn.
| Date | Event | Type | Phase |
|---|---|---|---|
| October 19, 2026 est. | Next quarterly earnings (projected) | Earnings | — |
| April 15, 2028 | A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2) | Trial Milestone | Phase 3 |
| May 1, 2028 | A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors | Trial Milestone | Phase 1 |
| August 15, 2028 | A Study of ERAS-4001 in Patients With Advanced or Metastatic Solid Tumors. | Trial Milestone | Phase 1 |
Track ERAS alongside other companies. Add it to a watchlist and see every catalyst on one calendar.
Open ERAS in the trackerTrial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.
Last updated 2026-10-14.